These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38133187)

  • 1. Biochemical Stability and Microbial Control of Reconstituted DaxibotulinumtoxinA-lanm for Injection.
    Ellis K; Thach T; Gallagher CJ
    Toxins (Basel); 2023 Dec; 15(12):. PubMed ID: 38133187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A.
    Solish N; Carruthers J; Kaufman J; Rubio RG; Gross TM; Gallagher CJ
    Drugs; 2021 Dec; 81(18):2091-2101. PubMed ID: 34787840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines.
    Humphrey S; Dover JS; Bowsher RR; Clancy A; Liu Y; Prawdzik G; Gallagher CJ
    Aesthet Surg J; 2023 Sep; 43(10):1189-1193. PubMed ID: 37051886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials.
    Gallagher CJ; Bowsher RR; Clancy A; Dover JS; Humphrey S; Liu Y; Prawdzik G
    Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DaxibotulinumtoxinA-lanm (Daxxify™): A Comprehensive Overview.
    Salame N; Eber AE; Dover J
    Skin Therapy Lett; 2023 Jul; 28(4):1-3. PubMed ID: 37440610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product.
    Dowdy SF; Gallagher CJ; Vitarella D; Brown J
    Expert Opin Drug Deliv; 2023; 20(9):1157-1166. PubMed ID: 37847051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).
    Bertucci V; Solish N; Kaufman-Janette J; Yoelin S; Shamban A; Schlessinger J; Snyder D; Gallagher C; Liu Y; Shears G; Rubio RG
    J Am Acad Dermatol; 2020 Apr; 82(4):838-845. PubMed ID: 31791824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of DaxibotulinumtoxinA for Injection on Brow Position and Frontalis Muscle Activity Following Treatment of Glabellar Lines.
    Solish N; Kane MAC; Biesman BS; Brown J; Gallagher CJ
    Aesthet Surg J; 2023 Nov; 43(Suppl 1):S1-S9. PubMed ID: 36095026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of reconstituted and stored botulinum toxin type A: an electrophysiologic and visual study in the auricular muscle of the rabbit.
    Jabor MA; Kaushik R; Shayani P; Ruiz-Razura A; Smith BK; Morimoto KW; Cohen BE
    Plast Reconstr Surg; 2003 Jun; 111(7):2419-26; discussion 2427-31. PubMed ID: 12794491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection.
    Glogau R; Kontis TC; Liu Y; Gallagher CJ
    Dermatol Surg; 2021 Dec; 47(12):1579-1584. PubMed ID: 34417396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Glabellar Lines by Age and Race: Subgroup Analysis of the SAKURA Clinical Trials.
    Solish N; Burgess CM; Weinkle SH; Ablon G; Brown J; Kooken K; Rubio RG
    Aesthet Surg J; 2023 Feb; 43(2):205-214. PubMed ID: 36087303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving Durable Forehead Line Outcomes With DaxibotulinumtoxinA: Early Experience in Real-World Clinical Practice.
    Lafkas M
    Aesthet Surg J Open Forum; 2024; 6():ojae023. PubMed ID: 38828476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Glabellar Injection Technique With DaxibotulinumtoxinA for Injection on Brow Position.
    Bertucci V; Green JB; Fezza JP; Brown J; Gallagher CJ; Solish N
    Aesthet Surg J; 2023 Nov; 43(Suppl 1):S10-S18. PubMed ID: 36322141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study.
    Fabi SG; Cohen JL; Green LJ; Dhawan S; Kontis TC; Baumann L; Gross TM; Gallagher CJ; Brown J; Rubio RG
    Dermatol Surg; 2021 Jan; 47(1):48-54. PubMed ID: 32773446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complexing Protein-Free Botulinum Neurotoxin A Formulations: Implications of Excipients for Immunogenicity.
    Martin MU; Frevert J; Tay CM
    Toxins (Basel); 2024 Feb; 16(2):. PubMed ID: 38393178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging the Gap: Sustained Treatment Effect of Glabellar Lines With Twice-A-Year Treatment With DaxibotulinumtoxinA.
    Dover JS; Solish N; Gross TM; Gallagher CJ; Brown J
    Dermatol Surg; 2023 Sep; 49(9):862-864. PubMed ID: 37384899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency and Quality of Reconstituted Botulinum Neurotoxin Type A According to Storage Temperatures.
    Park KY; Han HS; Kim JH; Kim HB; Seo SJ
    Dermatol Surg; 2020 Dec; 46(12):1657-1660. PubMed ID: 33252895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program.
    Cohen JL; Green LJ; Beer KR; Liu Y; Gallagher CJ
    Dermatol Surg; 2021 Apr; 47(4):511-515. PubMed ID: 33587381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature.
    Nedergaard H; Vestergaard S; Jensen PT; Kristiansen MW; Jensen MB; Ostergaard PB; Norsell T; Bjerre J
    Clin Ther; 2008 Jul; 30(7):1309-15. PubMed ID: 18691990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DAXI (DaxibotulinumtoxinA) - An Innovative Approach for Frown Lines.
    Mussarat A; Mustafa MS; Azam ST; Nafees Uddin MM; Nasrullah RMU; Siddiq MA
    Int J Gen Med; 2023; 16():1267-1269. PubMed ID: 37065981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.